Hu, L., Sun, Y., Luo, J., He, X., Ye, M., Li, G., . . . Chang, C. (2019). Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression. Oncogene.
Styl cytowania ChicagoHu, Linyi, et al. "Targeting TR4 Nuclear Receptor With Antagonist Bexarotene Increases Docetaxel Sensitivity to Better Suppress the Metastatic Castration-resistant Prostate Cancer Progression." Oncogene 2019.
Styl cytowania MLAHu, Linyi, et al. "Targeting TR4 Nuclear Receptor With Antagonist Bexarotene Increases Docetaxel Sensitivity to Better Suppress the Metastatic Castration-resistant Prostate Cancer Progression." Oncogene 2019.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..